echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Roche collaborated on the development of potential "first-in-class" drugs for "non-druggable" targets

    Roche collaborated on the development of potential "first-in-class" drugs for "non-druggable" targets

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    PhoreMost today announced a number of target discovery R&D collaborations


    PhoreMost focuses on developing potential "first-in-class" drugs


    The SITESEEKER platform reveals innovative, unintended, therapeutically useful drug targets in the entire human proteome


    "The collaboration with Roche is a testament to the capabilities and comprehensive utilization of our SITESEEKER platform, and further validates the potential and wide applicability


    Original English:

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.